Literature DB >> 24265476

Progress and challenges in RSV prophylaxis and vaccine development.

Lia M Haynes1.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 24265476     DOI: 10.1093/infdis/jit512

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  22 in total

1.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

2.  Qingkailing Injection () for Treatment of Children Pneumonia Induced by Respiratory Syncytial Virus: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shuai He; Wen-Shi Li; Ya-Jun Luo; Chen-Li Ye; Zhong-Yi Zhang
Journal:  Chin J Integr Med       Date:  2017-08-17       Impact factor: 1.978

Review 3.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

4.  Repurposing staples for viruses: applying peptide design to RSV prophylaxis.

Authors:  Sarah P Katen; Terence S Dermody
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

Review 5.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

6.  Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010-2014: the importance of birth month.

Authors:  R M Reeves; P Hardelid; R Gilbert; J Ellis; H Zhao; M Donati; R Pebody
Journal:  Epidemiol Infect       Date:  2016-02-26       Impact factor: 4.434

Review 7.  Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Authors:  Lindsay Broadbent; Helen Groves; Michael D Shields; Ultan F Power
Journal:  Influenza Other Respir Viruses       Date:  2015-07       Impact factor: 4.380

Review 8.  Innate immune recognition of respiratory syncytial virus infection.

Authors:  Tae Hoon Kim; Heung Kyu Lee
Journal:  BMB Rep       Date:  2014-04       Impact factor: 4.778

9.  Epidemiology of viral-associated acute lower respiratory tract infection among children <5 years of age in a high HIV prevalence setting, South Africa, 2009-2012.

Authors:  Cheryl Cohen; Sibongile Walaza; Jocelyn Moyes; Michelle Groome; Stefano Tempia; Marthi Pretorius; Orienka Hellferscee; Halima Dawood; Meera Chhagan; Fathima Naby; Summaya Haffejee; Ebrahim Variava; Kathleen Kahn; Susan Nzenze; Akhona Tshangela; Anne von Gottberg; Nicole Wolter; Adam L Cohen; Babatyi Kgokong; Marietjie Venter; Shabir A Madhi
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

10.  Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations.

Authors:  André Ricardo Ribas Freitas; Maria Rita Donalisio
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-03-29       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.